Starpharma: VivaGel® Condom Receives Regulatory Approval in Canada
13 Setembro 2016 - 2:55AM
Business Wire
Starpharma Holdings Ltd (ASX: SPL) (OTCQX: SPHRY) today
announced it had been granted a medical device license for the
VivaGel® condom by the Canadian regulatory authority, Health
Canada.
Starpharma’s marketing partner, Ansell (ASX: ANN), plans to
launch the VivaGel® condom in Canada as soon as possible under the
LifeStyles® Dual Protect™ brand.
The VivaGel® condom is a world-first product based on innovative
Australian technology. It is the only condom of its type, providing
barrier protection and incorporating the proprietary compound,
astodrimer sodium (SPL7013, VivaGel®) in the condom lubricant.
Starpharma Chief Executive Officer, Dr Jackie Fairley, said,
“The approval by Health Canada marks a further key commercial
milestone for the VivaGel® condom product, and is very significant
as the first North American approval for the product.”
Jeyan Heper, Ansell’s President and General Manager, Sexual
Wellness Global Business Unit said “Ansell's mission is to provide
innovative solutions for safety, well-being and peace of mind. We
pride ourselves on our innovative products and the LifeStyles® Dual
Protect™ condom is a great example of this, combining a
high-quality condom with Starpharma's VivaGel®, a patented
anti-viral technology.”
Regulatory reviews continue for the VivaGel® condom in a number
of other geographic regions with further approvals anticipated in
the coming months.
In May 2016, Starpharma and Ansell announced that VivaGel®
condoms were provided to Australian athletes ahead of the Olympics
in Rio de Janeiro. The antiviral condoms are also available for
Australian athletes at the Paralympics.
About VivaGel®
VivaGel® has been proven in laboratory studies to inactivate up
to 99.9% of HIV (human immunodeficiency virus), HSV (herpes simplex
virus) and HPV (human papillomavirus), which are viruses that cause
STIs. VivaGel® was also recently shown in laboratory studies to
have potent antiviral activity against the Zika virus at levels
significantly below the concentration in the Dual Protect™ condom.
It is now known that Zika virus can be sexually transmitted.
Customers in Canada can pre-order LifeStyles® Dual Protect™
condoms at www.lifestyles.com/dual-protect, as of Wednesday 14
September 2016.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160912006570/en/
Media:WE Buchan ConsultingRebecca Wilson, +61 417
382 391rwilson@buchanwe.com.auArthur Chan, +61 2 9237
2805achan@buchanwe.com.auorStarpharma:Dr Jackie Fairley, +61
3 8532 2704Chief Executive OfficerNigel Baade, +61 3 8532 2704CFO
and Company
Secretaryinvestor.relations@starpharma.comwww.starpharma.com
Starpharma (ASX:SPL)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Starpharma (ASX:SPL)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024